Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 9 ... and medium-term cancer risk for RA patients using anti-TNF therapies: infliximab, adalimumab, and etanercept. Details of the study appear in the November issue of Arthritis & ...
2009 NOV 23 ... for employees with RA were calculated. Costs of the tumor necrosis factor antagonist adalimumab were compared with those of other RA treatments. Default Parameters were based on ...
2009 NOV 16 ... Greece, "The recombinant human IgG1 monoclonal antibody specific for human TNF-a adalimumab (Humira) has been recently introduced for the treatment of moderate/severe psoriasis. ...
2009 NOV 23 ... in Canada and the United States: alefacept, efalizumab, etanercept, infliximab, adalimumab, and ustekinumab," researchers in Montreal, Canada report. "Biologic ...
2009 NOV 2 ... in RA (GO-AFTER) study demonstrated that patients with RA previously treated with adalimumab, etanercept or infliximab responded to, and maintained response to, SIMPONI through one ...
2009 NOV 23 ... Index score (PASI 75). Pooled NNTs were 1.3 (infliximab), 1.5 (ustekinumab 90 mg), 1.6 (adalimumab and ustekinumab 45 mg), 2.3 (etanercept), 4.1 (efalizumab), and 5.6 (alefacept). The ...
2009 NOV 9 ... rheumatoid arthritis, and the names of the individual DMARDs of interest (abatacept, adalimumab, anakinra, auranofin, aurothioglucose, aurothiomalate, D-penicillamine, etanercept, ...
2009 NOV 1 ... if repair of bone erosions, defined as regression of erosion scores, occurs during adalimumab treatment of patients with rheumatoid arthritis (RA). Fifty-two patients with RA, naive ...
2009 NOV 23 ... drug levels and antibody formation between patients with RA receiving infliximab and adalimumab." "69 patients with RA fulfilling the 1987 American College of ...
2009 NOV 16 ... New investigation results, 'Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab,' are detailed in a study published in ...
2009 NOV 16 ... prevent diseases, but ensure a better quality of life for all." Keywords: Adalimumab, Aging, Atopic Dermatitis, Audiology, Autoimmune Diseases, Autoimmune Disorder, ...
2009 NOV 23 ... the agent are the leading reasons for its use ahead of Humira. Keywords: Adalimumab, Amgen Inc., Biotechnology Business, Biotechnology Company, Centocor Inc., ...
2009 NOV 23 ... groups of patients have an elevated incidence of nail dystrophy. The biologic therapies adalimumab, alefacept, efalizumab, etanercept, and infliximab have demonstrated clinically ...
2009 NOV 2 ... adherence, use of medical services, and treatment costs when patients using either adalimumab (Humira=AE) or etanercept (Enbrel=AE) obtained these medications through specialty or ...
2009 NOV 2 ... Enbrel's safety is a leading reason for its use ahead of Humira. Keywords: Adalimumab, Amgen Inc., Arthritis, Biotechnology Business, Biotechnology Company, Centocor Inc., ...
